Myeloma Paper of the Day, July 3rd, suggested by Robert Orlowski
Robert Orlowski shared a post on X:
“Myeloma Paper of the Day: Small study of ixazomib/cyclophosphamide/dexamethasone in newly diagnosed POEMS syndrome patients finds overall hematologic response rate of 80% (8/10) with 30% complete response, overall serum VEGF response rate and neurological response were 100% and 83.3%.”
Source: Robert Orlowski/X
Authors: Haiyan He, Nan Hou, Xi Chen, Yaqi Song, Wanting Qiang, Jin Liu, Jing Lu, Weijun Fu and Juan Du.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023